Top Markets
#1 0G 0G +38.08%
#2 Axelar Axelar +22.24%
#3 Fake World Assets Fake World Assets +21.37%
#4 Bless Bless +19.68%
#5 Full Moon Full Moon +18.88%
#6 VVS Finance VVS Finance +18.18%
#7 Zora Zora +17.80%
#8 StonkBroker StonkBroker +16.79%
#9 Merlin's Seal BTC Merlin's Seal BTC +16.45%
#10 ADO Protocol ADO Protocol +15.64%
Coin of the day
0G 0G
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

3378
Classement en actions #13050
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and... Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.
Prix de l'action
$3.91
Capitalisation boursière
$524.79M
Changement (1 jour)
-0.71%
Changement (1 an)
-
Pays
CN
Échange Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)

Catégorie

Healthcare
Nombre d'actions en circulation pour Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)
Nombre d'actions en circulation au August 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Hanx Biopharmaceuticals (Wuhan) Co., Ltd., le nombre actuel d'actions en circulation est de 0. À la fin de August 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH